Skip to content
Peptigraph home

ATTAIN-1: Orforglipron Phase 3 trial (NCT05869903)

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Registry record checked

At a glance

Phase
Phase 3
Status
Active, not recruiting
Enrolment
3,127
actual
Start
5 Jun 2023 (actual)
Primary completion
25 Jul 2025 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05869903 study arms
ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboPrimary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron-matching placebo, administered orally once daily (QD), for a period of 72 weeks.
6 mg OrforglipronExperimentalDrug: OrforglipronPrimary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 milligrams (mg) and escalated every 4 weeks until reaching a dose of 6 mg at week 8, which was then maintained up to week 72.
12 mg OrforglipronExperimentalDrug: OrforglipronPrimary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 12 mg at week 12, which was then maintained up to week 72.
36 mg OrforglipronExperimentalDrug: OrforglipronPrimary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks until reaching a dose of 36 mg at week 20, which was then maintained up to week 72.
Endpoints

Primary endpoint

NCT05869903 primary outcomes
MeasureTime frame
Percent Change From Baseline in Body Weight (Primary Treatment Period)Baseline, Week 72
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05869903 secondary outcomes
MeasureTime frame
Change From Baseline in Waist Circumference (Primary Treatment Period)Baseline, Week 72
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment PeriodBaseline, Week 72
Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment PeriodBaseline, Week 72
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment PeriodBaseline, Week 72
Change From Baseline in HbA1c (Primary Treatment Period)Baseline, Week 72
Change From Baseline in Fasting Serum Glucose (FSG) (Primary Treatment Period)Baseline, Week 72
Percent Change From Baseline in Fasting Insulin (Primary Treatment Period)Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment PeriodBaseline, Week 72
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical Component and Mental Component) Scores - (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) - Primary Treatment PeriodBaseline, Week 72
Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)Baseline, Week 176
Time to Onset of Type 2 Diabetes (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)Baseline through Week 176, Baseline through Week 190
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05869903.

ATTAIN-1 as published in the New England Journal of Medicine

ATTAIN-1 randomised participants 3:3:3:4 to orforglipron 6, 12 or 36 mg or placebo daily for 72 weeks, as an adjunct to diet and physical activity.[2]

Weight changed by -7.5%, -8.4% and -11.2% on 6, 12 and 36 mg against -2.1% on placebo.[2]

On 36 mg, 54.6% lost 10% or more, 36.0% lost 15% or more and 18.4% lost 20% or more, against 12.9%, 5.9% and 2.8% on placebo.[2]

Adverse events caused discontinuation in 5.3 to 10.3% of orforglipron patients and 2.7% of placebo patients.[2]

The subgroup aged 65 and over

The post hoc analysis covered 616 randomised participants aged 65 or older across the two phase 3 trials.[3]

In the ATTAIN-1 older subgroup, weight changed by -7.9%, -11.3% and -13.0% with the three orforglipron doses, against -1.6% with placebo.[3]

Sources

  1. 1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
  3. 3Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026

Found an error? Report a correction.